



Chinese Pharmaceutical Association  
Institute of Materia Medica, Chinese Academy of Medical Sciences

Acta Pharmaceutica Sinica B

[www.elsevier.com/locate/apsb](http://www.elsevier.com/locate/apsb)  
[www.sciencedirect.com](http://www.sciencedirect.com)



CORRECTION

# Author correction to ‘Approved HIV reverse transcriptase inhibitors in the past decade’ [Acta Pharmaceutica Sinica B 12 (2022) 1567–1590]



Guangdi Li<sup>a</sup>, Yali Wang<sup>a,\*</sup>, Erik De Clercq<sup>b,\*</sup>

<sup>a</sup>Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha 410078, China

<sup>b</sup>Rega Institute for Medical Research, Department of Microbiology and Immunology, KU Leuven, Leuven B-3000, Belgium

The authors regret that the trade name “Acriptega” should be replaced by “Kocitaf” in this article, because the “Acriptega” represents the antiviral regimen of TDF + FTC + DTG, and the

“Kocitaf” represents the TAF + FTC + DTG regimen. Although it does not affect the conclusion, it is an obvious error. The authors apologize for any inconvenience caused to the journal and readers.

DOI of original article: <https://doi.org/10.1016/j.apsb.2021.11.009>.

\*Corresponding authors. Tel./fax: +32 1637 3755.

E-mail addresses: [wangyali@csu.edu.cn](mailto:wangyali@csu.edu.cn) (Yali Wang), [erik.declercq@kuleuven.be](mailto:erik.declercq@kuleuven.be) (Erik De Clercq).

Peer review under the responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

<https://doi.org/10.1016/j.apsb.2023.06.004>

2211-3835 © 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).